Stephen R Plymate
Overview
Explore the profile of Stephen R Plymate including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
8616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, et al.
J Clin Invest
. 2024 Apr;
134(11).
PMID: 38687617
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7....
2.
Uo T, Ojo K, Sprenger C, Epilepsia K, Perera B, Damodarasamy M, et al.
Mol Cancer Ther
. 2024 Mar;
23(7):973-994.
PMID: 38507737
Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Nonspecific inhibitors of glycolysis have not been utilized...
3.
Neeb A, Figueiredo I, Bogdan D, Cato L, Stober J, Jimenez-Vacas J, et al.
Mol Cancer Ther
. 2024 Feb;
23(6):791-808.
PMID: 38412481
Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR that drives transcriptional activity in CRPC...
4.
Wright J, Schenk J, Gulati R, Beatty S, VanDoren M, Lin D, et al.
Cancer
. 2024 Feb;
130(12):2108-2119.
PMID: 38353455
Background: Active surveillance (AS) is increasingly used to monitor patients with lower risk prostate cancer (PCa). The Prostate Cancer Active Lifestyle Study (PALS) was a randomized controlled trial to determine...
5.
Sychev Z, Day A, Bergom H, Larson G, Ali A, Ludwig M, et al.
Mol Cancer Res
. 2024 Feb;
22(5):452-464.
PMID: 38345532
Implications: Overall, our study highlights the importance of protein-based identification when compared with RNA and provides a rich resource of new and feasible targets for clinical assay development and in...
6.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, et al.
Lab Invest
. 2023 Aug;
103(11):100245.
PMID: 37652207
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical...
7.
Sychev Z, Day A, Bergom H, Larson G, Ali A, Ludwig M, et al.
bioRxiv
. 2023 Aug;
PMID: 37577653
Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform to emergent aggressive variant prostate cancer (AVPC) which has neuroendocrine (NE)-like...
8.
Uo T, Ojo K, Sprenger C, Epilepsia K, Perera B, Damodarasamy M, et al.
bioRxiv
. 2023 Jul;
PMID: 37461469
Purpose: Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Non-specific inhibitors of glycolysis have not been...
9.
Nyquist M, Coleman I, Lucas J, Li D, Hanratty B, Meade H, et al.
Cancer Res
. 2023 Jun;
83(17):2938-2951.
PMID: 37352376
Significance: Determining the molecular pathways by which supraphysiological androgens promote growth arrest and treatment responses in prostate cancer provides opportunities for biomarker-selected clinical trials and the development of strategies to...
10.
Bae S, Bergom H, Day A, Greene J, Sychev Z, Larson G, et al.
Front Endocrinol (Lausanne)
. 2023 Apr;
14:1093332.
PMID: 37065756
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes,...